Home > Rozibafusp alfa effective and tolerable in rheumatoid arthritis

Rozibafusp alfa effective and tolerable in rheumatoid arthritis

For the first time, safety and tolerability results were reported for multiple ascending doses of rozibafusp alfa in patients with rheumatoid arthritis [1]. This showed greater numerical improvement from baseline in Patient Global Assessments (PtGA) and Physician Global Assessments (PhGA) as well as a non-linear, target-mediated disposition.

Dr Lubna Abuqayyas (Amgen, USA) presented the interim analysis of a phase 1b study looking at the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of rozibafusp alfa in patients with rheumatoid arthritis. Rozibafusp alfa (AMG 570) is a first-in-class bispecific antibody-peptide conjugate targeting T- and B-cell activity.

The 34 participants were aged between 18 and 75 years with active rheumatoid arthritis (defined as a disease activity score [DAS28-CRP] >2). Patients were randomised 3:1 to receive rozibafusp alfa ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on




Notice: Undefined variable: conference_obj in /home/daan/projects/medicalconferences_test/wp-content/themes/writers-blogily-child/template-parts/content-widget-toc.php on line 43

Warning: Creating default object from empty value in /home/daan/projects/medicalconferences_test/wp-content/themes/writers-blogily-child/template-parts/content-widget-toc.php on line 44

Notice: Undefined property: stdClass::$category_parent in /home/daan/projects/medicalconferences_test/wp-content/themes/writers-blogily-child/template-parts/content-widget-toc.php on line 45

Notice: Undefined property: stdClass::$term_id in /home/daan/projects/medicalconferences_test/wp-content/themes/writers-blogily-child/template-parts/content-widget-toc.php on line 53

Notice: Undefined property: stdClass::$term_id in /home/daan/projects/medicalconferences_test/wp-content/themes/writers-blogily-child/template-parts/content-widget-toc.php on line 64